Defects In Membrane Repair Research Articles

Plasma membrane repair defect in Alzheimer's disease neurons is driven by the reduced dysferlin expression.

Alzheimer's disease (AD) is the most common neurodegenerative disease, and a defect in neuronal plasma membrane repair could exacerbate neurotoxicity, neuronal death, and disease progression. In this study, application of AD patient cerebrospinal fluid (CSF) and recombinant human Aβ to otherwise healthy neurons induces defective neuronal plasma membrane repair invitro and exvivo. We identified Aβ as the biochemical component in patient CSF leading to compromised repair capacity and depleting Aβ rescued repair capacity. These elevated Aβ levels reduced expression of dysferlin, a protein that facilitates membrane repair, by altering autophagy and reducing dysferlin trafficking to sites of membrane injury. Overexpression of dysferlin and autophagy inhibition rescued membrane repair. Overall, these findings indicate an AD pathogenic mechanism where Aβ impairs neuronal membrane repair capacity and increases susceptibility to cell death. This suggests that membrane repair could be therapeutically targeted in AD to restore membrane integrity and reduce neurotoxicity and neuronal death.

Compromised Plasma Membrane Repair Contributes to Neuronal Cell Death and Neurodegeneration During Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common neurodegenerative disease and involves accumulation of intracellular amyloid beta (Aβ) in the early stages of the disease. Aβ has been shown to compromise neuronal cell membrane integrity by increasing membrane permeability, elevating intracellular calcium concentrations, and Aβ directly penetrating and damaging the neuronal cell membrane. Damage to the cell membrane requires a rapid and effcient repair mechanism to restore the barrier function of the membrane and avoid cell death. Here, we aimed to study the effects of intracellular Aβ on neuronal cell membrane repair. To determine if membrane permeability is compromised in vivo, we stained 6-month FVB and APP/PS1 brain sections with anti-IgG. We observed a significant increase in IgG positivity in the APP/PS1 tissue as compared to the FVB brains. We repeated this with post-mortem frontal lobe tissue and observed a significant increase in IgG-positivity in the AD samples as compared to the non-AD. To assess the effect of neuronal membrane repair in AD patients, we treated mouse neuroblastomas (N2A) and primary mouse hippocampal neurons with non-AD and AD patient cerebrospinal fluid (CSF) at a 1:100 dilution or 1μM recombinant human Aβ42. We conducted laser damage assays and observed a membrane repair defect in these neuronal cell models. We explored the biochemical components of the CSF that may be contributing to this induced repair defect, we measured the Aβ42 by ELISA and stratified Aβ42 concentration by the corresponding CSF AUC. We observed a positive correlation between Aβ42 concentrations and reduced membrane repair capacity. We sought to determine the mechanism of the reduced membrane repair capacity by assessing the expression levels of membrane repair proteins and observed decreased dysferlin in cell models, 6-month APP/PS1 mouse models, and human postmortem tissues with high levels of Aβ. Overexpression of dysferlin in the AD cell models can increase dysferlin expression and restore membrane repair capacity in neurons treated with AD CSF samples or recombinant Aβ42. We have determined this reduction in repair capacity is due to reduced dysferlin expression, and future studies will determine the mechanism leading to dysferlin downregulation. This work was supported by The Ohio State University College of Medicine Dean’s Discovery Grants Program. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Neuronal Membrane Repair Defect as a Contributor to Amyloid Beta Pathogenesis in Alzheimer's Disease

Alzheimer’s Disease (AD) is a common neurodegenerative disease that displays two hallmark protein accumulations in the brain – extracellular amyloid beta (Aβ) and intracellular hyperphosphorylated tau. Aβ has been shown to directly penetrate the neuronal cell membrane and damage the membrane. This compromises membrane integrity, increases membrane permeability that alters membrane conductance and elevates intracellular calcium concentrations which contribute to reactive oxygen species production and mitochondrial dysfunction. This damage to the plasma membrane requires a quick and efficient repair mechanism to restore the barrier function of the membrane and avoid neuronal cell death. However, a defect in membrane repair has not been examined as a contributor to AD. Here, we aimed to assess membrane repair capacity in AD in vitro models as a potential contributor to neuronal death. To assess the effect of Aβ on membrane repair kinetics, we exposed primary mouse hippocampal neurons to 1μM recombinant human Aβ42 (rhAβ42) for 16 hours prior to experimentation. Additionally, we treated wildtype neuronal cells with healthy and AD patient with elevated levels of Aβ (PSEN1 M146L mutation) cortical neuron iPSC conditioned media. We also exposed primary mouse hippocampal neurons to cerebrospinal fluid (CSF) from non-AD and AD patients. Treated cells were challenged with an established laser damage assay where a two-photon laser is used to damage the cell membrane in the presence of FM4-64 dye. Dye fluorescence at the injury site is used as a proxy for membrane repair kinetics. Lastly, we investigated autoantibody production targeting proteins involved in membrane repair in non-AD and AD sera and CSF via custom ELISAs. Overall, we observed an induced membrane repair defect when wildtype neuronal cells are treated with rhAβ42, AD iPSC conditioned media, and AD CSF. We also observed a significant increase in autoantibody production in AD biofluids as compared to the non-AD controls. Autoantibody levels were inversely correlated with efficient membrane repair capacity and positively correlated with Aβ concentrations. These results illustrate Aβ’s role in impairing neuronal membrane repair capacity, and the potential contribution of autoantibodies targeting membrane repair proteins in AD. This work is supported by The Ohio State University Dean's Discovery grant and Dept. of Physiology & Cell Biology Nishikawara Student Research grant. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Trafficking of Annexins during Membrane Repair in Human Skeletal Muscle Cells.

Defects in membrane repair contribute to the development of muscular dystrophies, such as Miyoshi muscular dystrophy 1, limb girdle muscular dystrophy (LGMD), type R2 or R12. Deciphering membrane repair dysfunctions in the development of muscular dystrophies requires precise and detailed knowledge of the membrane repair machinery in healthy human skeletal muscle cells. Using correlative light and electron microscopy (CLEM), we studied the trafficking of four members of the annexin (ANX) family, in myotubes damaged by laser ablation. Our data support a model in which ANXA4 and ANXA6 are recruited to the disruption site by propagating as a wave-like motion along the sarcolemma. They may act in membrane resealing by proceeding to sarcolemma remodeling. On the other hand, ANXA1 and A2 exhibit a progressive cytoplasmic recruitment, likely by interacting with intracellular vesicles, in order to form the lipid patch required for membrane resealing. Once the sarcolemma has been resealed, ANXA1 is released from the site of the membrane injury and returns to the cytosol, while ANXA2 remains accumulated close to the wounding site on the cytoplasmic side. On the other side of the repaired sarcolemma are ANXA4 and ANXA6 that face the extracellular milieu, where they are concentrated in a dense structure, the cap subdomain. The proposed model provides a basis for the identification of cellular dysregulations in the membrane repair of dystrophic human muscle cells.

Annexin-A6 in Membrane Repair of Human Skeletal Muscle Cell: A Role in the Cap Subdomain.

Defects in membrane repair contribute to the development of some muscular dystrophies, highlighting the importance to decipher the membrane repair mechanisms in human skeletal muscle. In murine myofibers, the formation of a cap subdomain composed notably by annexins (Anx) is critical for membrane repair. We applied membrane damage by laser ablation to human skeletal muscle cells and assessed the behavior of annexin-A6 (AnxA6) tagged with GFP by correlative light and electron microscopy (CLEM). We show that AnxA6 was recruited to the site of membrane injury within a few seconds after membrane injury. In addition, we show that the deficiency in AnxA6 compromises human sarcolemma repair, demonstrating the crucial role played by AnxA6 in this process. An AnxA6-containing cap-subdomain was formed in damaged human myotubes in about one minute. Through transmission electron microscopy (TEM), we observed that extension of the sarcolemma occurred during membrane resealing, which participated in forming a dense lipid structure in order to plug the hole. By properties of membrane folding and curvature, AnxA6 helped in the formation of this tight structure. The compaction of intracellular membranes—which are used for membrane resealing and engulfed in extensions of the sarcolemma—may also facilitate elimination of the excess of lipid and protein material once cell membrane has been repaired. These data reinforce the role played by AnxA6 and the cap subdomain in membrane repair of skeletal muscle cells.

Exon Skipping in a Dysf-Missense Mutant Mouse Model

Limb girdle muscular dystrophy 2B (LGMD2B) is without treatment and caused by mutations in the dysferlin gene (DYSF). One-third is missense mutations leading to dysferlin aggregation and amyloid formation, in addition to defects in sarcolemmal repair and progressive muscle wasting. Dysferlin-null mouse models do not allow study of the consequences of missense mutations. We generated a new mouse model (MMex38) carrying a missense mutation in exon 38 in analogy to a clinically relevant human DYSF variant (DYSF p.Leu1341Pro). The targeted mutation induces all characteristics of missense mutant dysferlinopathy, including a progressive dystrophic pattern, amyloid formation, and defects in membrane repair. We chose U7 small nuclear RNA (snRNA)-based splice switching to demonstrate a possible exon-skipping strategy in this new animal model. We show that Dysf exons 37 and 38 can successfully be skipped in vivo. Overall, the MMex38 mouse model provides an ideal tool for preclinical development of treatment strategies for dysferlinopathy.

Down-regulation of acid sphingomyelinase and neutral sphingomyelinase-2 inversely determines the cellular resistance to plasmalemmal injury by pore-forming toxins.

Bacterial pore-forming toxins compromise plasmalemmal integrity, leading to Ca2+ influx, leakage of the cytoplasm, and cell death. Such lesions can be repaired by microvesicular shedding or by the endocytic uptake of the injured membrane sites. Cells have at their disposal an entire toolbox of repair proteins for the identification and elimination of membrane lesions. Sphingomyelinases catalyze the breakdown of sphingomyelin into ceramide and phosphocholine. Sphingomyelin is predominantly localized in the outer leaflet, where it is hydrolyzed by acid sphingomyelinase (ASM) after lysosomal fusion with the plasma membrane. The magnesium-dependent neutral sphingomyelinase (NSM)-2 is found at the inner leaflet of the plasmalemma. Because either sphingomyelinase has been ascribed a role in the cellular stress response, we investigated their role in plasma membrane repair and cellular survival after treatment with the pore-forming toxins listeriolysin O (LLO) or pneumolysin (PLY). Jurkat T cells, in which ASM or NSM-2 was down-regulated [ASM knockdown (KD) or NSM-2 KD cells], showed inverse reactions to toxin-induced membrane damage: ASM KD cells displayed reduced toxin resistance, decreased viability, and defects in membrane repair. In contrast, the down-regulation of NSM-2 led to an increase in viability and enhanced plasmalemmal repair. Yet, in addition to the increased plasmalemmal repair, the enhanced toxin resistance of NSM-2 KD cells also appeared to be dependent on the activation of p38/MAPK, which was constitutively activated, whereas in ASM KD cells, the p38/MAPK activation was constitutively blunted.-Schoenauer, R., Larpin, Y., Babiychuk, E. B., Drücker, P., Babiychuk, V. S., Avota, E., Schneider-Schaulies, S., Schumacher, F., Kleuser, B., Köffel, R., Draeger, A. Down-regulation of acid sphingomyelinase and neutral sphingomyelinase-2 inversely determines the cellular resistance to plasmalemmal injury by pore-forming toxins.

Contribution of Membrane Repair Defects to Skeletal Muscle Inflammation

Inflammation is a significant contributor to multiple skeletal muscle diseases, however the mechanisms that facilitate these inflammatory responses have not been fully characterized. Idiopathic immune myopathies are a group of disorders involving chronic damage to skeletal muscle due to extensive inflammation triggered by autoimmune responses and provides a model to further understand general mechanisms of inflammation. Chronic inflammation leads to degeneration of muscle structure and function resulting in severe proximal muscle weakness. T‐cell‐ and antibody‐mediated processes are involved in the progression of disease, however the mechanism leading to pathogenesis remains unknown. Two animal models have recently provided insight into the pathogenic mechanisms of myositis. Synaptotagmin VII null (SytVII−/−) mice display impaired sarcolemmal repair capacity and develop mild myositis, suggesting that antigen presentation of internal skeletal muscle proteins may play a role in initiating an autoimmune response. A more robust model of myositis combines the Syt VII−/− model with a FoxP3 mutation (FoxP3−/Y/Syt VII−/−). This mouse strain combines impaired membrane repair with regulatory T‐cell deficiency. Adoptive transfer of lymph node cells from FoxP3−/Y/Syt VII−/− mice to RAG‐1 mice lacking T‐ or B‐cells results in significant muscle inflammation. The current project examined the contribution of defective sarcolemmal repair to the pathogenesis of myositis. Sarcolemmal membrane repair is a conserved process where disruptions in the lipid bilayer are actively resealed to maintain cellular integrity. Previous studies established the cellular framework of the membrane repair process utilizes exocytotic and endocytotic vesicle trafficking to restore membrane integrity. Previous work by our lab and others identified TRIM72, a member of the Tripartite Motif family of E3 ubiquitin ligases, as a critical component of the membrane repair process. Our studies here identified novel autoantibodies against TRIM proteins in patient sera. Using an adoptive transfer model to induce myositis in mice, we show that membrane repair is compromised in skeletal muscle distal to the initial site of inflammation. We also demonstrate that exogenous delivery of antibodies against TRIM proteins can compromise membrane repair in healthy skeletal muscle. Our data indicate that defects in membrane repair associated with the progression of myositis lead to TRIM protein exposure to the extracellular space and that the autoantibodies produced against TRIM proteins further compromise membrane repair and exacerbate inflammation.Support or Funding InformationNational Institute of Arthritis and Musculoskeletal and Skin Diseases, MDA, The Ohio State University Center for Clinical and Translational Science

A novel perspective for burn-induced myopathy: Membrane repair defect.

Myopathy is a common complication of severe burn patients. One potential cause of this myopathy could be failure of the plasma membrane to undergo repair following injuries generated from toxin or exercise. The aim of this study is to assess systemic effect on muscle membrane repair deficiency in burn injury. Skeletal muscle fibers isolated from burn-injured mice were damaged with a UV laser and dye influx imaged confocally to evaluate membrane repair capacity. Membrane repair failure was also tested in burn-injured mice subjected to myotoxin or treadmill exercise. We further used C2C12 myotubules and animal models to investigate the role of MG53 in development of burn-induced membrane repair defect. We demonstrated that skeletal muscle myofibers in burn-injured mice showed significantly more dye uptake after laser damage than controls, indicating a membrane repair deficiency. Myotoxin or treadmill exercise also resulted in a higher-grade repair defect in burn-injured mice. Furthermore, we observed that burn injury induced a significant decrease in MG53 levels and its dimerization in skeletal muscles. Our findings highlight a new mechanism that implicates membrane repair failure as an underlying cause of burn-induced myopathy. And, the disorders in MG53 expression and MG53 dimerization are involved in this cellular pathology.

GRAF1 deficiency blunts sarcolemmal injury repair and exacerbates cardiac and skeletal muscle pathology in dystrophin-deficient mice.

BackgroundThe plasma membranes of striated muscle cells are particularly susceptible to rupture as they endure significant mechanical stress and strain during muscle contraction, and studies have shown that defects in membrane repair can contribute to the progression of muscular dystrophy. The synaptotagmin-related protein, dysferlin, has been implicated in mediating rapid membrane repair through its ability to direct intracellular vesicles to sites of membrane injury. However, further work is required to identify the precise molecular mechanisms that govern dysferlin targeting and membrane repair. We previously showed that the bin–amphiphysin–Rvs (BAR)–pleckstrin homology (PH) domain containing Rho-GAP GTPase regulator associated with focal adhesion kinase-1 (GRAF1) was dynamically recruited to the tips of fusing myoblasts wherein it promoted membrane merging by facilitating ferlin-dependent capturing of intracellular vesicles. Because acute membrane repair responses involve similar vesicle trafficking complexes/events and because our prior studies in GRAF1-deficient tadpoles revealed a putative role for GRAF1 in maintaining muscle membrane integrity, we postulated that GRAF1 might also play an important role in facilitating dysferlin-dependent plasma membrane repair.MethodsWe used an in vitro laser-injury model to test whether GRAF1 was necessary for efficient muscle membrane repair. We also generated dystrophin/GRAF1 doubledeficient mice by breeding mdx mice with GRAF1 hypomorphic mice. Evans blue dye uptake and extensive morphometric analyses were used to assess sarcolemmal integrity and related pathologies in cardiac and skeletal muscles isolated from these mice.ResultsHerein, we show that GRAF1 is dynamically recruited to damaged skeletal and cardiac muscle plasma membranes and that GRAF1-depleted muscle cells have reduced membrane healing abilities. Moreover, we show that dystrophin depletion exacerbated muscle damage in GRAF1-deficient mice and that mice with dystrophin/GRAF1 double deficiency phenocopied the severe muscle pathologies observed in dystrophin/dysferlin-double null mice. Consistent with a model that GRAF1 facilitates dysferlin-dependent membrane patching, we found that GRAF1 associates with and regulates plasma membrane deposition of dysferlin.ConclusionsOverall, our work indicates that GRAF1 facilitates dysferlin-dependent membrane repair following acute muscle injury. These findings indicate that GRAF1 might play a role in the phenotypic variation and pathological progression of cardiac and skeletal muscle degeneration in muscular dystrophy patients.Electronic supplementary materialThe online version of this article (doi:10.1186/s13395-015-0054-6) contains supplementary material, which is available to authorized users.

The Phenotype of Dysferlin-Deficient Mice Is Not Rescued by Adeno-Associated Virus–Mediated Transfer of Anoctamin 5

Mutations in dysferlin and anoctamin 5 are the cause of muscular disorders, with the main presentations as limb-girdle muscular dystrophy or Miyoshi type of distal myopathy. Both these proteins have been implicated in sarcolemmal resealing. On the basis of similarities in associated phenotypes and protein functions, we tested the hypothesis that ANO5 protein could compensate for dysferlin absence. We first defined that the main transcript of ANO5 expressed in skeletal muscle is the 22-exon full-length isoform, and we demonstrated that dysferlin-deficient (Dysf (prmd)) mice have lower Ano5 expression levels, an observation that further enhanced the rational of the tested hypothesis. We then showed that AAV-mediated transfer of human ANO5 (hANO5) did not lead to apparent toxicity in wild-type mice. Finally, we demonstrated that AAV-hANO5 injection was not able to compensate for dysferlin deficiency in the Dysf (prmd) mouse model or improve the membrane repair defect seen in the absence of dysferlin. Consequently, overexpressing hANO5 does not seem to provide a valuable therapeutic strategy for dysferlin deficiency.

The Heme Oxygenase 1 Inducer (CoPP) Protects Human Cardiac Stem Cells against Apoptosis through Activation of the Extracellular Signal-regulated Kinase (ERK)/NRF2 Signaling Pathway and Cytokine Release

Intracoronary delivery of c-kit-positive human cardiac stem cells (hCSCs) is a promising approach to repair the infarcted heart, but it is severely limited by the poor survival of donor cells. Cobalt protoporphyrin (CoPP), a well known heme oxygenase 1 inducer, has been used to promote endogenous CO generation and protect against ischemia/reperfusion injury. Therefore, we determined whether preconditioning hCSCs with CoPP promotes CSC survival. c-kit-positive, lineage-negative hCSCs were isolated from human heart biopsies. Lactate dehydrogenase release assays demonstrated that preconditioning CSCs with CoPP markedly enhanced cell survival after oxidative stress induced by H(2)O(2), concomitant with up-regulation of heme oxygenase 1, COX-2, and anti-apoptotic proteins (BCL2, BCL2-A1, and MCL-1) and increased phosphorylation of NRF2. Apoptotic cytometric assays showed that pretreatment of CSCs with CoPP enhanced the cells' resistance to apoptosis induced by oxidative stress. Conversely, knocking down HO-1, COX-2, or NRF2 by shRNA gene silencing abrogated the cytoprotective effects of CoPP. Further, preconditioning CSCs with CoPP led to a global increase in release of cytokines, such as EGF, FGFs, colony-stimulating factors, and chemokine ligand. Conditioned medium from cells pretreated with CoPP conferred naive CSCs remarkable resistance to apoptosis, demonstrating that cytokines released by preconditioned cells play a key role in the anti-apoptotic effects of CoPP. Preconditioning CSCs with CoPP also induced an increase in the phosphorylation of Erk1/2, which are known to modulate multiple pro-survival genes. These results potentially provide a simple and effective strategy to enhance survival of CSCs after transplantation and, therefore, their efficacy in repairing infarcted myocardium.

Correction of Membrane Repair Defects in Dysferlin Deficient Muscle Following AAV5 Gene Transfer (S55.006)

Correction of Membrane Repair Defects in Dysferlin Deficient Muscle Following AAV5 Gene Transfer (S55.006)

Additive Phenotype of MG53 and Dysferlin Deficiencies in Membrane Repair Function of Skeletal Muscle Fibers

Dysferlin and MG53 have been implicated as members of the sarcolemma repair machinery. Skeletal muscle fibers isolated from mice lacking expression of one or the other protein display defective membrane repair process following acute injuries. Our previous studies show that MG53 can nucleate the assembly of the membrane repair machinery by facilitating translocation of intracellular vesicles to membrane injury sites. Dysferlin appears to participate in Ca2+-dependent fusion of these vesicles for formation of a repair patch, but dysferlin itself cannot translocate to the injury site in the absence of MG53. To test the complementary function of MG53 and dysferlin in cell membrane repair, we generated a double knockout mouse lacking both MG53 and dysferlin. While serum creatine kinase (CK) levels of dysferlin-/-, mg53-/-, and wild-type mice were not significantly different from each other, CK levels of the mg53-/-dysferlin-/- mice were significantly elevated at resting condition. This suggests a more severe membrane repair defect. Plasma membrane targeted UV-irradiation of isolated skeletal muscle fibers in the presence of a membrane impermeant dye (FM1-43) was used to directly assay membrane repair. This experimental procedure was modified from previously established protocols for a quantitative assessment of the muscle membrane repair capacity. Compared with dysferlin-/- and mg53-/- fibers, significant elevated entry of FM1-43 dye was observed in mg53-/-dysferlin-/- muscle following UV-irradiation. These results suggest that the involvement of these two proteins in the membrane repair mechanism is more complicated than that as two points along a linear pathway. The additive effects of MG53 and dysferlin in muscle membrane repair suggest the possibility that these two proteins may either sense different membrane injury signals, or that they may act at different compartments of the sarcolemma membrane (caveolae or transverse-tubule network).

PTRF Anchors MG53 to Cell Injury Site for Initiation of Membrane Repair

Abstract Plasma membrane repair is an essential process for maintenance of homeostasis at the cellular and tissue levels while compromised repair capacity contributes to degenerative human diseases. Our recent studies show that MG53 is essential for muscle membrane repair, and defects in MG53 function are linked to muscular dystrophy and cardiac dysfunction. Here we report PTRF (polymerase I and transcript release factor), a gene known to regulate caveolae membrane structure, is an indispensible component of the membrane repair machinery. PTRF acts as a docking protein for MG53 during membrane repair potentially by binding exposed membrane cholesterol at the injury site. Cells lacking expression of endogenous PTRF show defective trafficking of MG53 to membrane injury sites. A mutation in PTRF associated with human disease results in aberrant nuclear localization of PTRF and disrupts MG53 function in membrane resealing. While RNAisilencing of PTRF leads to defective muscle membrane repair, overexpression of PTRF can rescue membrane repair defects in dystrophic muscle. Our data suggests that membranedelimited interaction between MG53 and PTRF contributes to initiation of cell membrane repair, which can be an attractive target for treatment or prevention of tissue injury in human diseases.

A Novel Cellular Defect in Diabetes

OBJECTIVESkeletal muscle myopathy is a common diabetes complication. One possible cause of myopathy is myocyte failure to repair contraction-generated plasma membrane injuries. Here, we test the hypothesis that diabetes induces a repair defect in skeletal muscle myocytes.RESEARCH DESIGN AND METHODSMyocytes in intact muscle from type 1 (INS2Akita+/−) and type 2 (db/db) diabetic mice were injured with a laser and dye uptake imaged confocally to test repair efficiency. Membrane repair defects were also assessed in diabetic mice after downhill running, which induces myocyte plasma membrane disruption injuries in vivo. A cell culture model was used to investigate the role of advanced glycation end products (AGEs) and the receptor for AGE (RAGE) in development of this repair defect.RESULTSDiabetic myocytes displayed significantly more dye influx after laser injury than controls, indicating a repair deficiency. Downhill running also resulted in a higher level of repair failure in diabetic mice. This repair defect was mimicked in cultured cells by prolonged exposure to high glucose. Inhibition of the formation of AGE eliminated this glucose-induced repair defect. However, a repair defect could be induced, in the absence of high glucose, by enhancing AGE binding to RAGE, or simply by increasing cell exposure to AGE.CONCLUSIONSBecause one consequence of repair failure is rapid cell death (via necrosis), our demonstration that repair fails in diabetes suggests a new mechanism by which myopathy develops in diabetes.

Annexin-A5 assembled into two-dimensional arrays promotes cell membrane repair

Eukaryotic cells possess a universal repair machinery that ensures rapid resealing of plasma membrane disruptions. Before resealing, the torn membrane is submitted to considerable tension, which functions to expand the disruption. Here we show that annexin-A5 (AnxA5), a protein that self-assembles into two-dimensional (2D) arrays on membranes upon Ca2+ activation, promotes membrane repair. Compared with wild-type mouse perivascular cells, AnxA5-null cells exhibit a severe membrane repair defect. Membrane repair in AnxA5-null cells is rescued by addition of AnxA5, which binds exclusively to disrupted membrane areas. In contrast, an AnxA5 mutant that lacks the ability of forming 2D arrays is unable to promote membrane repair. We propose that AnxA5 participates in a previously unrecognized step of the membrane repair process: triggered by the local influx of Ca2+, AnxA5 proteins bind to torn membrane edges and form a 2D array, which prevents wound expansion and promotes membrane resealing.

Polymerase Transcriptase Release Factor (PTRF) Anchors MG53 Protein to Cell Injury Site for Initiation of Membrane Repair

Plasma membrane repair is an essential process for maintenance of homeostasis at the cellular and tissue levels, whereas compromised repair capacity contributes to degenerative human diseases. Our recent studies show that MG53 is essential for muscle membrane repair, and defects in MG53 function are linked to muscular dystrophy and cardiac dysfunction. Here we report that polymerase I and transcript release factor (PTRF), a gene known to regulate caveolae membrane structure, is an indispensable component of the membrane repair machinery. PTRF acts as a docking protein for MG53 during membrane repair potentially by binding exposed membrane cholesterol at the injury site. Cells lacking expression of endogenous PTRF show defective trafficking of MG53 to membrane injury sites. A mutation in PTRF associated with human disease results in aberrant nuclear localization of PTRF and disrupts MG53 function in membrane resealing. Although RNAi silencing of PTRF leads to defective muscle membrane repair, overexpression of PTRF can rescue membrane repair defects in dystrophic muscle. Our data suggest that membrane-delimited interaction between MG53 and PTRF contributes to initiation of cell membrane repair, which can be an attractive target for treatment or prevention of tissue injury in human diseases.

Recombinant MG53 Binds Lipid Signals on Damaged Cell Membranes to Increase Membrane Repair Capacity

Plasma membrane repair is a highly conserved mechanism that appears in most eukaryotic cells. While a simple lipid bilayer will reseal through thermodynamic principles, the presence of a cytoskeleton results in the native plasma membrane being held under tension, thus some disruptions the plasma membrane cannot spontaneously reseal. Previous studies established that plasma membrane repair is an active process involving translocation of intracellular vesicles to the injury site and fusion of these vesicles to form a repair “patch”. An emerging concept in cell biology establishes this intrinsic membrane repair/regeneration process is a fundamental aspect of normal physiology and that disruption of this mechanism underlies the progression of many human diseases, including cardiovascular disease, neurodegeneration, ischemic injury and muscular dystrophy. We recently discovered that mitsugumin 53 (MG53/TRIM72) is an essential component of the cell membrane repair. In this study we tested the translational value of targeting MG53 function in tissue repair and regenerative medicine using in vitro cell based assays and animal models. While native MG53 protein is restricted to striated muscle, beneficial effects against cellular injuries are present in non-muscle cells with overexpression of MG53. In addition to the intracellular action of MG53, acute injury of the cell membrane leads to exposure of lipid signals that can be detected by MG53, allowing recombinant MG53 to repair membrane damage when provided in the extracellular space. Human MG53 protein retains dose-dependent protection against membrane disruption in both muscle and non-muscle cells. Intravenous delivery of MG53 protein is safe in rodent models, with suitable pharmacokinetic properties that are highly effective in restoring or preventing localized damage to muscle tissues. Our data indicate the MG53 protein is an attractive biological reagent for restoration of membrane repair defects in human diseases.

Membrane Repair Defects in Muscular Dystrophy Are Linked to Altered Interaction between MG53, Caveolin-3, and Dysferlin

Defective membrane repair can contribute to the progression of muscular dystrophy. Although mutations in caveolin-3 (Cav3) and dysferlin are linked to muscular dystrophy in human patients, the molecular mechanism underlying the functional interplay between Cav3 and dysferlin in membrane repair of muscle physiology and disease has not been fully resolved. We recently discovered that mitsugumin 53 (MG53), a muscle-specific TRIM (Tri-partite motif) family protein (TRIM72), contributes to intracellular vesicle trafficking and is an essential component of the membrane repair machinery in striated muscle. Here we show that MG53 interacts with dysferlin and Cav3 to regulate membrane repair in skeletal muscle. MG53 mediates active trafficking of intracellular vesicles to the sarcolemma and is required for movement of dysferlin to sites of cell injury during repair patch formation. Mutations in Cav3 (P104L, R26Q) that cause retention of Cav3 in Golgi apparatus result in aberrant localization of MG53 and dysferlin in a dominant-negative fashion, leading to defective membrane repair. Our data reveal that a molecular complex formed by MG53, dysferlin, and Cav3 is essential for repair of muscle membrane damage and also provide a therapeutic target for treatment of muscular and cardiovascular diseases that are linked to compromised membrane repair.